Human mesenchymal stem cells (hMSCs) are multipotent cells used in cell therapy research. One of the problems involving hMSCs is the possibility of genetic instability during in vitro expansion required to obtain a suitable number of cells for clinical applications. The cytokinesis-block micronucleus (CBMN) assay measures genetic instability by analyzing the presence of micronucleus (MN), nucleoplasmic bridges (NPBs), and nuclear buds (NBUDs) in binucleated cells. The present study describes modifications in the CBMN assay methodology to analyze genetic instability in hMSCs isolated from the umbilical vein and in vitro expanded. The best protocol to achieve binucleated hMSCs with preserved cytoplasm was as follows: cytochalasin B concentration (4.0 μg/mL), use of hypotonic treatment (3 min), and the fixative solution (9 methanol:1 acetic acid). These adaptations were reproduced in three hMSC primary cell cultures and also in XP4PA and A549 cell lines. The frequency of hMSCs treated with mitomycin-C presenting MN was lower than that with other nuclear alterations, indicating that the hMSCs contain mechanisms to avoid a high level of chromosomal breaks. However, a high frequency of cells with NPBs was detected and spontaneous anaphase bridges under normal hMSC in vitro culture were observed. Considering that anaphase bridges are characteristic alterations in tumor cells, the CBMN assay is indicated as an important tool associated with other genetic analyses in order to ensure the safe clinical use of hMSCs in cell therapy.
Get full access to this article
View all access options for this article.
References
1.
DominiciM, Le BlancK, MuellerI, Slaper-CortenbachI, MariniF, KrauseD, DeansR, KeatingA, ProckopDJ and HorwitzE. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 8:315–317.
2.
Meirelles LdaS and NardiNB. (2009). Methodology, biology and clinical applications of mesenchymal stem cells. Front Biosci, 14:4281–4298.
CaplanAI and CorreaD. (2011). The MSC: an injury drugstore. Cell Stem Cell, 9:11–15.
5.
Di TrapaniM, BassiG, RicciardiM, FontanaE, BifariF, PacelliL, GiacomelloL, PozzobonM, FéronF, et al. (2013). Comparative study of immune regulatory properties of stem cells derived from different tissues. Stem Cells Dev, 22:2990–3002.
6.
HassR, KasperC, BöhmS and JacobsR. (2011). Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal, 14:9–12.
7.
BernardoME, CometaAM, PagliaraD, VintiL, RossiF, CristantielliR, PalumboG and LocatelliF. (2011). Ex vivo expansion of mesenchymal stromal cells. Best Pract Res Clin Haematol, 24:73–81.
8.
SpeesJL, GregoryCA, SinghH, TuckerHA, PeisterA, LynchPJ, HsuSC, SmithJ and ProckopDJ. (2004). Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy. Mol Ther, 9:747–756.
9.
CaisanderG, ParkH, FrejK, LindqvistJ, BerghC, LundinK and HansonC. (2006). Chromosomal integrity maintained in five human embryonic stem cell lines after prolonged in vitro culture. Chromosome Res, 14:131–137.
10.
BernardoME, ZaffaroniN, NovaraF, CometaAM, AvanziniMA, MorettaA, MontagnaD, MaccarioR, VillaR, et al. (2007). Human bone marrow–derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer, 67:9142–9149.
11.
ZhangZX, GuanLX, ZhangK, WangS, CaoPC, WangYH, WangZ and DaiLJ. (2007). Cytogenetic analysis of human bone marrow-derived mesenchymal stem cells passaged in vitro. Cell Biol Int, 31:645–648.
12.
ChoumerianouDM, DimitriouH, PerdikogianniC, MartimianakiG, RiminucciM and KalmantiM. (2008). Study of oncogenic transformation in ex vivo expanded mesenchymal cells, from paediatric bone marrow. Cell Prolif, 41:909–922.
13.
FarihaMM, ChuaKH, TanGC, TanAE and HayatiAR. (2011). Human chorion-derived stem cells: changes in stem cell properties during serial passage. Cytotherapy, 13:582–593.
14.
PoloniA, MauriziG, BabiniL, SerraniF, BerardinelliE, ManciniS, CostantiniB, DiscepoliG and LeoniP. (2011). Human mesenchymal stem cells from chorionic villi and amniotic fluid are not susceptible to transformation after extensive in vitro expansion. Cell Transplant, 20:643–654.
15.
RoubelakisMG, BitsikaV, ZagouraD, TrohatouO, PappaKI, MakridakisM, AntsaklisA, VlahouA and AnagnouNP. (2011). In vitro and in vivo properties of distinct populations of amniotic fluid mesenchymal progenitor cells. J Cell Mol Med, 15:1896–1913.
16.
FongCY, SubramanianA, BiswasA, GauthamanK, SrikanthP, HandeMP and BongsoA. (2010). Derivation efficiency, cell proliferation, freeze-thaw survival, stem-cell properties and differentiation of human Wharton's jelly stem cells. Reprod Biomed Online, 21:391–401.
17.
GauthamanK, FongCY, SuganyaCA, SubramanianA, BiswasA, ChoolaniM and BongsoA. (2012). Extra-embryonic human Wharton's jelly stem cells do not induce tumorigenesis, unlike human embryonic stem cells. Reprod Biomed Online, 24:235–246.
18.
GoldringCE, DuffyPA, BenvenistyN, AndrewsPW, Ben-DavidU, EakinsR, FrenchN, HanleyNA, KellyL, et al. (2011). Assessing the safety of stem cell therapeutics. Cell Stem Cell, 8:618–628.
19.
BinatoR, de Souza FernandezT, Lazzarotto-SilvaC, Du RocherB, MencalhaA, PizzattiL, BouzasLF and AbdelhayE. (2013). Stability of human mesenchymal stem cells during in vitro culture: considerations for cell therapy. Cell Prolif, 46:10–22.
20.
FietzT, BerdelWE, RiederH, ReufiB, HoppH, ThielE and KnaufWU. (1999). Culturing human umbilical cord blood: a comparison of mononuclear vs CD34+ selected cells. Bone Marrow Transplant, 23:1109–1115.
21.
KimJW, KimSY, ParkSY, KimYM, KimJM, LeeMH and RyuHM. (2004). Mesenchymal progenitor cells in the human umbilical cord. Ann Hematol, 83:733–738.
22.
BochkovNP, VoroninaES, KosyakovaNV, LiehrT, RzhaninovaAA, KatosovaLD, PlatonovaVI and Gol'dshteinDV. (2007). Chromosome variability of human multipotent mesenchymal stromal cells. Bull Exp Biol Med, 143:122–126.
23.
Meza-ZepedaLA, NoerA, DahlJA, MicciF, MyklebostO and CollasP. (2008). High-resolution analysis of genetic stability of human adipose tissue stem cells cultured to senescence. J Cell Mol Med, 12:553–563.
24.
BuyanovskayaOA, KuleshovNP, NikitinaVA, VoroninaES, KatosovaLD and BochkovNP. (2009). Spontaneous aneuploidy and clone formation in adipose tissue stem cells during different periods of culturing. Bull Exp Biol Med, 148:109–112.
25.
SareenD, McMillanE, EbertAD, ShelleyBC, JohnsonJA, MeisnerLF and SvendsenCN. (2009). Chromosome 7 and 19 trisomy in cultured human neural progenitor cells. PLoS One, 4:e7630
26.
TakeuchiM, TakeuchiK, OzawaY, KoharaA and MizusawaH. (2009). Aneuploidy in immortalized human mesenchymal stem cells with non-random loss of chromosome 13 in culture. In Vitro Cell Dev Biol Anim, 45:290–299.
27.
Ben-DavidU, MaysharY and BenvenistyN. (2011). Large-scale analysis reveals acquisition of lineage-specific chromosomal aberrations in human adult stem cells. Cell Stem Cell, 9:97–102.
28.
UeyamaH, HoribeT, HinotsuS, TanakaT, InoueT, UrushiharaH, KitagawaA and KawakamiK. (2012). Chromosomal variability of human mesenchymal stem cells cultured under hypoxic conditions. J Cell Mol Med, 16:72–82.
29.
Ben-DavidU, MaysharY and BenvenistyN. (2012). Significant acquisition of chromosomal aberrations in human adult mesenchymal stem cells: response to Sensebe´ et al. Cell Stem Cell, 10:10–11.
30.
WangY, HusoDL, HarringtonJ, KellnerJ, JeongDK, TurneyJ and McNieceIK. (2005). Outgrowth of a transformed cell population derived from normal human BM mesenchymal stem cell culture. Cytotherapy, 7:509–519.
31.
TangDQ, WangQ, BurkhardtBR, LitherlandSA, AtkinsonMA and YangLJ. (2012). In vitro generation of functional insulin-producing cells from human bone marrow-derived stem cells, but long-term culture running risk of malignant transformation. Am J Stem Cells, 1:114–127.
32.
TarteK, GaillardJ, LatailladeJJ, FouillardL, BeckerM, MossafaH, TchirkovA, RouardH, HenryC, et al.; Société Française de Greffe de Moelle et Thérapie Cellulaire. (2010). Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. Blood, 115:1549–1553.
33.
SensebéL, TarteK, GalipeauJ, KramperaM, MartinI, PhinneyDG, ShiY; MSC Committee of the International Society for Cellular Therapy. (2012). Limited acquisition of chromosomal aberrations in human adult mesenchymal stromal cells. Cell Stem Cell, 10:9–10.
34.
FenechM. (2000). The in vitro micronucleus technique. Mutat Res, 455:81–95.
35.
NarinA and TuncayO. (2012). Relationships between malignant melanoma and chromosome damage in human peripheral blood lymphocytes. Asian Pac J Cancer Prev, 13:5229–5232.
AiresGM, MeirelesJR, OliveiraPC, OliveiraJL, AraújoEL, PiresBC, CruzES, JesusNF, PereiraCA and CerqueiraEM. (2011). Micronuclei as biomarkers for evaluating the risk of malignant transformation in the uterine cervix. Genet Mol Res, 10:1558–1564.
38.
GayathriB, KalyaniR, HemalathaA and VasaviB. (2012). Significance of micronucleus in cervical intraepithelial lesions and carcinoma. J Cytol, 29:236–240.
39.
SingarajuM, SingarajuS, ParwaniR and WanjariS. (2012). Cytogenetic biomonitoring in petrol station attendants: a micronucleus study. J Cytol, 29:1–5.
40.
FenechM, Kirsch-VoldersM, NatarajanAT, SurrallesJ, CrottJW, ParryJ, NorppaH, EastmondDA, TuckerJD and ThomasP. (2011). Molecular mechanisms of micronucleus, nucleoplasmic bridge and nuclear bud formation in mammalian and human cells. Mutagenesis, 26:125–132.
41.
BonassiS, El-ZeinR, BolognesiC and FenechM. (2011). Micronuclei frequency in peripheral blood lymphocytes and cancer risk: evidence from human studies. Mutagenesis, 26:93–100.
42.
El-ZeinR, VralA and EtzelCJ. (2011). Cytokinesis-blocked micronucleus assay and cancer risk assessment. Mutagenesis, 26:101–106.
43.
McHughMK, LopezMS, HoCH, SpitzMR, EtzelCJ and El-ZeinRA. (2013). Use of the cytokinesis-blocked micronucleus assay to detect gender differences and genetic instability in a lung cancer case-control study. Cancer Epidemiol Biomarkers Prev, 22:135–145.
44.
BullCF, Beetstra-HillS, Benassi-EvansBJ, CrottJW, KimuraM, TeoT, WuJ and FenechMF. (2011). Application and adaptation of the in vitro micronucleus assay for the assessment of nutritional requirements of cells for DNA damage prevention. Mutagenesis, 26:193–197.
45.
BullCF, MayrhoferG, ZeegersD, MunGL, HandeMP and FenechMF. (2012). Folate deficiency is associated with the formation of complex nuclear anomalies in the cytokinesis-block micronucleus cytome assay. Environ Mol Mutagen, 53:311–323.
46.
TavaresJCM, CornélioDA, SilvaNB, MouraCEB, QueirozJDF, SáJC, AlvesCJr and Batistuzzo de MedeirosSR. (2009). Effect of titanium surface modified by plasma energy source on genotoxic response in vitro. Toxicol, 262:138–145.
47.
DegrandiTH, de OliveiraIM, d'AlmeidaGS, GarciaCR, VillelaIV, GuechevaTN, RosaRM and HenriquesJA. (2010). Evaluation of the cytotoxicity, genotoxicity and mutagenicity of diphenyl ditelluride in several biological models. Mutagenesis, 25:257–269.
48.
Benassi-EvansB and FenechM. (2011). Chronic alcohol exposure induces genome damage measured using the cytokinesis-block micronucleus cytome assay and aneuploidy in human B lymphoblastoid cell lines. Mutagenesis, 26:421–429.
49.
GonzálezNV, NikoloffN, SoloneskiS and LarramendyML. (2011). A combination of the cytokinesis-block micronucleus cytome assay and centromeric identification for evaluation of the genotoxicity of dicamba. Toxicol Lett, 207:204–212.
50.
AndresE, MolinariJ, RemouéN, Sá-RochaVM, BarrichelloC and HurtadoSP. (2012). Successful micronucleus testing with the EPI/001 3D reconstructed epidermis model: preliminary findings. Mutat Res, 743:36–41.
51.
TakahashiK, TanabeK, OhnukiM, NaritaM, IchisakaT, TomodaK, YamanakaS. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 131:861–872.
52.
VinothKJ, HengBC, PoonepalliA, BanerjeeB, BalakrishnanL, LuK, HandeMP and CaoT. (2008). Human embryonic stem cells may display higher resistance to genotoxic stress as compared to primary explanted somatic cells. Stem Cells Dev, 17:599–607.
53.
LaustriatD, GideJ and PeschanskiM. (2010). Human pluripotent stem cells in drug discovery and predictive toxicology. Biochem Soc Trans, 38:1051–1057.
54.
TroskoJE and ChangCC. (2010). Factors to consider in the use of stem cells for pharmaceutic drug development and for chemical safety assessment. Toxicology, 270:18–34.
55.
VojnitsK and BremerS. (2010). Challenges of using pluripotent stem cells for safety assessments of substances. Toxicology, 270:10–17.
56.
WobusAM and LöserP. (2011). Present state and future perspectives of using pluripotent stem cells in toxicology research. Arch Toxicol, 85:79–117.
57.
DuarteDM, CornélioDA, CoradoC, MedeirosVK, de AraújoLA, CavalcantiGB and de MedeirosSR. (2012). Chromosomal characterization of cryopreserved mesenchymal stem cells from the human subendothelium umbilical cord vein. Regen Med, 7:147–157.
58.
Daya-GrosjeanL, JamesMR, DrougardC and SarasinA. (1987). An immortalized xeroderma pigmentosum, group C, cell line which replicates SV40 shuttle vectors. Mutat Res, 183:185–196.
59.
GiardDJ, AaronsonSA, TodaroGJ, ArnsteinP, KerseyJH, DosikH and ParksWP. (1973). In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst, 51:1417–1423.
60.
CovasDT, SiufiJL, SilvaAR and OrellanaMD. (2003). Isolation and culture of umbilical vein mesenchymal stem cells. Braz J Med Biol Res, 36:1179–1183.
61.
PanepucciRA, SiufiJL, SilvaWAJr, Proto-SiquieraR, NederL, OrellanaM, RochaV, CovasDT and ZagoMA. (2004). Comparison of gene expression of umbilical cord vein and bone marrow–derived mesenchymal stem cells. Stem Cells, 22:1263–1278.
62.
KadivarM, KhatamiS, MortazaviY, ShokrgozarMA, TaghikhaniM and SoleimaniM. (2006). In vitro cardiomyogenic potential of human umbilical vein-derived mesenchymal stem cells. Biochem Biophys Res Commun, 340:639–647.
63.
RomanovYA, SvintsitskayaVA and SmirnovVN. (2003). Searching for alternative sources of postnatal human mesenchymal stem cells: candidate MSC-like cells from umbilical cord. Stem Cells, 21:105–110.
64.
KohSH, KimKS, ChoiMR, JungKH, ParkKS, ChaiYG, RohW, HwangSJ, KoHJ, et al. (2008). Implantation of human umbilical cord-derived mesenchymal stem cells as a neuroprotective therapy for ischemic stroke in rats. Brain Res, 1229:233–248.
65.
IshigeI, Nagamura-InoueT, HondaMJ, HarnprasopwatR, KidoM, SugimotoM, NakauchiH and TojoA. (2009). Comparison of mesenchymal stem cells derived from arterial, venous, and Wharton's jelly explants of human umbilical cord. Int J Hematol, 90:261–269.
66.
LiM, ZhangSZ, GuoYW, CaiYQ, YanZJ, ZouZ, JiangXD, KeYQ, HeXY, et al. (2010). Human umbilical vein-derived dopaminergic-like cell transplantation with nerve growth factor ameliorates motor dysfunction in a rat model of Parkinson's disease. Neurochem Res, 35:1522–1529.
67.
MontesinosJJ, Flores-FigueroaE, Castillo-MedinaS, Flores-GuzmánP, Hernández-EstévezE, Fajardo-OrduñaG, OrozcoS and MayaniH. (2009). Human mesenchymal stromal cells from adult and neonatal sources: comparative analysis of their morphology, immunophenotype, differentiation patterns and neural protein expression. Cytotherapy, 11:163–176.
68.
HoJH, ChenYF, MaWH, TsengTC, ChenMH and LeeOK. (2011). Cell contact accelerates replicative senescence of human mesenchymal stem cells independent of telomere shortening and p53 activation: roles of Ras and oxidative stress. Cell Transplant, 20:1209–1220.
69.
SchillerZA, SchieleNR, SimsJK, LeeK and KuoCK. (2013). Adipogenesis of adipose-derived stem cells may be regulated via the cytoskeleton at physiological oxygen levels in vitro. Stem Cell Res Ther, 4:79
70.
ZhongW, TianK, ZhengX, LiL, ZhangW, WangS and QinJ. (2013). Mesenchymal stem cell and chondrocyte fates in a multishear microdevice are regulated by yes-associated protein. Stem Cells Dev, 22:2083–2093.
71.
RyuYJ, ChoTJ, LeeDS, ChoiJY and ChoJ. (2013). Phenotypic characterization and in vivo localization of human adipose-derived mesenchymal stem cells. Mol Cells, 35:557–564.
72.
KalantariH, GourabiH and BaharvandH. (2012). Adapted cytokinesis-block micronucleus assay (CBMN) for mouse embryonic stem cells. www.nature.com/protocolexchange/protocols/2355#/introduction.
73.
HenegariuO, HeeremaNA, Lowe WrightL, Bray-WardP, WardDC and VanceGH. (2001). Improvements in cytogenetic slide preparation: controlled chromosome spreading, chemical aging and gradual denaturing. Cytometry, 43:101–109.
74.
DengW, TsaoSW, LucasJN, LeungCS and CheungAL. (2003). A new method for improving metaphase chromosome spreading. Cytometry A, 51:46–51.
75.
MoynahanME, CuiTY and JasinM. (2001). Homology-directed DNA repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res, 61:4842–4850.
76.
ChangHC, TsaiJ, GuoYL, HuangYH, TsaiHN, TsaiPC and HuangW. (2003). Differential UVC-induced gadd45 gene expression in xeroderma pigmentosum cells. Biochem Biophys Res Commun, 305:1109–1115.
77.
FrosinaG. (2010). The bright and the dark sides of DNA repair in stem cells. J Biomed Biotechnol, 2010:845396
78.
FanJ, RobertC, JangYY, LiuH, SharkisS, BaylinSB and RassoolFV. (2011). Human induced pluripotent cells resemble embryonic stem cells demonstrating enhanced levels of DNA repair and efficacy of nonhomologous end-joining. Mutat Res, 713:8–17.
79.
LuoLZ, Gopalakrishna-PillaiS, NaySL, ParkSW, BatesSE, ZengX, IversonLE and O'ConnorTR. (2012). DNA repair in human pluripotent stem cells is distinct from that in non-pluripotent human cells. PLoS One, 7:e30541
80.
BrackerTU, GiebelB, SpanholtzJ, SorgUR, Klein-HitpassL, MoritzT and ThomaleJ. (2006). Stringent regulation of DNA repair during human hematopoietic differentiation: a gene expression and functional analysis. Stem Cells, 24:722–730.
81.
ChenMF, LinCT, ChenWC, YangCT, ChenCC, LiaoSK, LiuJM, LuCH and LeeKD. (2006). The sensitivity of human mesenchymal stem cells to ionizing radiation. Int J Radiat Oncol Biol Phys, 66:244–253.
82.
SugrueT, BrownJA, LowndesNF and CeredigR. (2013). Multiple facets of the DNA damage response contribute to the radioresistance of mouse mesenchymal stromal cell lines. Stem Cells, 31:137–145.
83.
OliverL, HueE, SéryQ, LafargueA, PecqueurC, ParisF and ValletteFM. (2013). Differentiation-related response to DNA breaks in human mesenchymal stem cells. Stem Cells, 31:800–807.
84.
ThomasP, UmegakiK and FenechM. (2003). Nucleoplasmic bridges are a sensitive measure of chromosome rearrangement in the cytokinesis-block micronucleus assay. Mutagenesis, 18:187–194.
85.
GlaserN and StopperH. (2012). Patulin: Mechanism of genotoxicity. Food Chem Toxicol, 50:1796–1801.
86.
KocamanAY, RencüzoğullarıE and TopaktaşM. (2012). In vitro investigation of the genotoxic and cytotoxic effects of thiacloprid in cultured human peripheral blood lymphocytes. Environ Toxicol. [Epub ahead of print]; DOI: 10.1002/tox.21790.
87.
DuanH, LengS, PanZ, DaiY, NiuY, HuangC, BinP, WangY, LiuQ, ChenW and ZhengY. (2009). Biomarkers measured by cytokinesis-block micronucleus cytome assay for evaluating genetic damages induced by polycyclic aromatic hydrocarbons. Mutat Res, 677:93–99.
88.
EbertR, UlmerM, ZeckS, Meissner-WeiglJ, SchneiderD, StopperH, SchuppN, KassemM and JakobF. (2006). Selenium supplementation restores the antioxidative capacity and prevents cell damage in bone marrow stromal cells in vitro. Stem Cells, 24:1226–1235.
FoudahD, RedaelliS, DonzelliE, BentivegnaA, MilosoM, DalpràL and TrediciG. (2009). Monitoring the genomic stability of in vitro cultured rat bone-marrow-derived mesenchymal stem cells. Chromosome Res, 17:1025–1039.
94.
JeongJO, HanJW, KimJM, ChoHJ, ParkC, LeeN, KimDW and YoonYS. (2011). Malignant tumor formation after transplantation of short-term cultured bone marrow mesenchymal stem cells in experimental myocardial infarction and diabetic neuropathy. Circ Res, 108:1340–1347.
95.
RenZ, WangJ, ZhuW, GuanY, ZouC, ChenZ and ZhangYA. (2011). Spontaneous transformation of adult mesenchymal stem cells from cynomolgus macaques in vitro. Exp Cell Res, 317:2950–2957.
96.
TassoR, AugelloA, Carida’M, PostiglioneF, TibilettiMG, BernasconiB, AstigianoS, FaisF, TruiniM, CanceddaR and PennesiG. (2009). Development of sarcomas in mice implanted with mesenchymal stem cells seeded onto bioscaffolds. Carcinogenesis, 30:150–157.
97.
Wislet-GendebienS, PouletC, NeirinckxV, HennuyB, SwinglandJT, LaudetE, SommerL, ShakovaO, BoursV and RogisterB. (2012). In vivo tumorigenesis was observed after injection of in vitro expanded neural crest stem cells isolated from adult bone marrow. PLoS One, 7:e46425
98.
XuS, De BeckerA, De RaeveH, Van CampB, VanderkerkenK and Van RietI. (2012). In vitro expanded bone marrow-derived murine (C57Bl/KaLwRij) mesenchymal stem cells can acquire CD34 expression and induce sarcoma formation in vivo. Biochem Biophys Res Commun, 424:391–397.
99.
GisselssonD. (2008). Classification of chromosome segregation errors in cancer. Chromosoma, 117:511–519.
100.
GisselssonD, PetterssonL, HöglundM, HeidenbladM, GorunovaL, WiegantJ, MertensF, Dal CinP, MitelmanF and MandahlN. (2000). Chromosomal breakage-fusion-bridge events cause genetic intratumor heterogeneity. Proc Natl Acad Sci U S A, 97:5357–5362.
101.
GisselssonD, BjörkJ, HöglundM, MertensF, Dal CinP, AkermanM and MandahlN. (2001). Abnormal nuclear shape in solid tumors reflects mitotic instability. Am J Pathol, 158:199–206.
102.
Gebre-MedhinS, BrobergK, JonsonT, GorunovaL, von SteyernFV, BrosjöO, JinY, GisselssonD, PanagopoulosI, MandahlN and MertensF. (2009). Telomeric associations correlate with telomere length reduction and clonal chromosome aberrations in giant cell tumor of bone. Cytogenet Genome Res, 124:121–127.
103.
HoffelderDR, LuoL, BurkeNA, WatkinsSC, GollinSM and SaundersWS. (2004). Resolution of anaphase bridges in cancer cells. Chromosoma, 112:389–397.
104.
HeimS and MitelmanF. (2009). Cancer Cytogenetics, 3rd edn. Wiley-Blackwell, New York.
105.
TusellL, PampalonaJ, SolerD, FríasC and GenescàA. (2010). Different outcomes of telomere-dependent anaphase bridges. Biochem Soc Trans, 38:1698–1703.
106.
FriasC, PampalonaJ, GenescaA and TusellL. (2012). Telomere dysfunction and genome instability. Front Biosci, 17:2181–2196.
107.
PampalonaJ, FríasC, GenescàA and TusellL. (2012). Progressive telomere dysfunction causes cytokinesis failure and leads to the accumulation of polyploid cells. PLoS Genet, 8:e1002679
108.
ZakovS, KinsellaM and BafnaV. (2013). An algorithmic approach for breakage-fusion-bridge detection in tumor genomes. Proc Natl Acad Sci U S A, 110:5546–5551.
109.
CaladoRT, CooperJN, Padilla-NashHM, SloandEM, WuCO, ScheinbergP, RiedT and YoungNS. (2012). Short telomeres result in chromosomal instability in hematopoietic cells and precede malignant evolution in human aplastic anemia. Leukemia, 26:700–707.
110.
ChakrabortyS, StarkJM, SunCL, ModiH, ChenW, O'ConnorTR, FormanSJ, BhatiaS and BhatiaR. (2012). Chronic myelogenous leukemia stem and progenitor cells demonstrate chromosomal instability related to repeated breakage-fusion-bridge cycles mediated by increased nonhomologous end joining. Blood, 119:6187–6197.
111.
ChanKL, NorthPS and HicksonID. (2007). BLM is required for faithful chromosome segregation and its localization defines a class of ultrafine anaphase bridges. EMBO J, 26:3397–3409.
112.
ChanKL and HicksonID. (2011). New insights into the formation and resolution of ultra-fine anaphase bridges. Semin Cell Dev Biol, 22:906–912.
113.
BaumannC, KörnerR, HofmannK and NiggEA. (2007). PICH, a centromere-associated SNF2 family ATPase, is regulated by Plk1 and required for the spindle checkpoint. Cell, 128:101–114.
114.
RouzeauS, CordelièresFP, Buhagiar-LabarchèdeG, HurbainI, Onclercq-DelicR, GembleS, Magnaghi-JaulinL, JaulinC and Amor-GuéretM. (2012). Bloom's syndrome and PICH helicases cooperate with topoisomerase IIα in centromere disjunction before anaphase. PLoS One, 7:e33905
115.
BarefieldC and KarlsederJ. (2012). The BLM helicase contributes to telomere maintenance through processing of late-replicating intermediate structures. Nucleic Acids Res, 40:7358–7367.
116.
RodrigueA, CoulombeY, JacquetK, GagnéJP, RoquesC, GobeilS, PoirierG and MassonJY. (2013). The RAD51 paralogs ensure cellular protection against mitotic defects and aneuploidy. J Cell Sci, 126(Pt 1):348–359.
117.
LarsenNB and HicksonID. (2013). RecQ Helicases: Conserved Guardians of Genomic Integrity. Adv Exp Med Biol, 767:161–184.
118.
ChanKL, Palmai-PallagT, YingS and HicksonID. (2009). Replication stress induces sister-chromatid bridging at fragile site loci in mitosis. Nat Cell Biol, 11:753–760.
119.
NaimV and RosselliF. (2009). The FANC pathway and mitosis: a replication legacy. Cell Cycle, 8:2907–2911.
120.
KaulichM, CubizollesF and NiggEA. (2012). On the regulation, function, and localization of the DNA-dependent ATPase PICH. Chromosoma, 121:395–408.
121.
JäägerK, IslamS, ZajacP, LinnarssonS and NeumanT. (2012). RNA-seq analysis reveals different dynamics of differentiation of human dermis- and adipose-derived stromal stem cells. PLoS One, 7:e38833
122.
SchäckLM, NoackS, WinklerR, JagodzinskiM, KrettekC, BüttnerM and HoffmannA. (2013). Analysis of surface protein expression in human bone marrow stromal cells: new aspects of culture-induced changes, inter-donor differences and intracellular expression. Stem Cells Dev [Epub ahead of print] PubMed PMID:23927592.
123.
DhillonVS, ThomasP, IarmarcovaiG, Kirsch-VoldersM, BonassiS and FenechM. (2011). Genetic polymorphisms of genes involved in DNA repair and metabolism influence micronucleus frequencies in human peripheral blood lymphocytes. Mutagenesis, 26:33–42.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
